Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.7K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.1K
6.1K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?

International journal of molecular sciences·2025
Same author

<i>Lentinula edodes</i> as a Source of Bioactive Compounds with Therapeutical Potential in Intestinal Inflammation and Colorectal Cancer.

International journal of molecular sciences·2025
Same author

Metastasis of Squamous Cell Carcinoma of the Larynx to the Right Adrenal Gland-A Case Report.

Clinics and practice·2025
Same author

COVID-19 Pandemic Conditions Affecting QoL and Mental Health of Oncology Patients in Poland.

Cancers·2025
Same author

Selenopolysaccharide Isolated from <i>Lentinula edodes</i> Mycelium Affects Human T-Cell Function.

International journal of molecular sciences·2024
Same author

The effect of incretin-based drugs on the riks of acute pancreatitis: a review.

Journal of diabetes and metabolic disorders·2024

Related Experiment Video

Updated: May 5, 2026

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

12.8K

[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].

Agnieszka Badora1, Beata Kaleta, Elzbieta Nowara

  • 1Klinika Onkologii Klinicznej i Doświadczalnej, Centrum Onkologii Instytut im. M. Skłodowskiej-Curie, Oddział w Gliwicach, Polska. agnieszka.k.badora@gmail.com

Ginekologia Polska
|November 27, 2013
PubMed
Summary

BRCA1 gene mutations increase hereditary breast and ovarian cancer risk. Even with risk-reducing surgeries, primary peritoneal cancer can still occur in mutation carriers, highlighting the need for comprehensive genetic diagnosis and surveillance.

More Related Videos

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

11.7K
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

16.2K

Related Experiment Videos

Last Updated: May 5, 2026

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

12.8K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

11.7K
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

16.2K

Area of Science:

  • Oncology
  • Genetics
  • Gynecologic Oncology

Background:

  • BRCA1 and BRCA2 gene mutations are major contributors to hereditary breast and ovarian cancers.
  • Risk-reducing salpingo-oophorectomy is a key strategy for gynecological cancer prevention in mutation carriers.
  • This procedure does not prevent primary peritoneal cancer.

Observation:

  • Two cases of BRCA1 mutation carriers with metachronous malignancies are presented.
  • The first patient developed breast cancer, then ovarian cancer post-prophylactic surgery.
  • The second patient had breast cancer, and later developed primary peritoneal cancer and ovarian cancer independently.

Findings:

  • Both patients with BRCA1 mutations developed advanced cancers.
  • The first patient had ovarian cancer despite prophylactic surgery.
  • The second patient presented with synchronous primary peritoneal and ovarian cancers, distinct from her breast cancer.

Implications:

  • Genetic diagnosis is crucial for personalized cancer risk assessment and management.
  • Comprehensive surveillance strategies are necessary for BRCA1 mutation carriers.
  • These cases underscore the limitations of current prophylactic measures against all gynecologic cancers in BRCA1 carriers.